共 50 条
- [1] First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti-IL-20 Monoclonal Antibody in Patients with PsoriasisPLOS ONE, 2015, 10 (08):Gottlieb, Alice B.Krueger, James G.Lundblad, Mia SandbergGothberg, MarieSkolnick, Brett E.
- [2] SAFETY AND TOLERABILITY OF THE ANTI-C5AR HUMANISED MONOCLONAL ANTIBODY NNC0151-0000 IN PATIENTS WITH RHEUMATOID ARTHRITIS: A PHASE 2, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE TRIALANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 684 - 685Daniluk, S.Skrumsager, B. K.Leszczynski, P.
- [3] Efficacy and Safety of NNC0142-0002, a Novel Human Monoclonal Antibody Targeting NKG2D: a Randomized, Double-Blind, Single-Dose Phase 2 Trial in Patients With Crohn's DiseaseGASTROENTEROLOGY, 2014, 146 (05) : S587 - S587Allez, MatthieuPetryka, RobertSkolnick, Brett E.Wisniewska-Jarosinska, Maria A.
- [4] Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis - A randomized, double-blind, placebo-controlled, dose-escalation trialARTHRITIS AND RHEUMATISM, 2002, 46 (12): : 3143 - 3150Choy, EHSIsenberg, DAGarrood, TFarrow, SIoannou, YBird, HCheung, NWilliams, BHazleman, BPrice, RYoshizaki, KNishimoto, NKishimoto, TPanayi, GS
- [5] MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trialANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (06) : 1058 - 1064Behrens, FrankTak, Paul P.Ostergaard, MikkelStoilov, RumenWiland, PiotrHuizinga, Thomas W.Berenfus, Vadym Y.Vladeva, StoyankaRech, JuergenRubbert-Roth, AndreaKorkosz, MariuszRekalov, DmitriyZupanets, Igor A.Ejbjerg, Bo J.Geiseler, JensFresenius, JuliaKorolkiewicz, Roman P.Schottelius, Arndt J.Burkhardt, Harald
- [6] Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis c virusHEPATOLOGY, 2007, 46 (05) : 1341 - 1349McHutchison, John G.Bacon, Bruce R.Gordon, Stuart C.Lawitz, EricShiffman, MitcheflAfdhal, Nezam H.Jacobson, Ira M.Muir, AndrewAl-Adhami, MohammedMorris, Mary L.Lekstrom-Himes, Julie A.Lekstrom-Himes, A.Efler, Susan M.Davis, Heather L.
- [7] Multiple doses of SHR-1222, a sclerostin monoclonal antibody, in postmenopausal women with osteoporosis: A randomized, double-blind, placebocontrolled, dose-escalation phase 1 trialFRONTIERS IN ENDOCRINOLOGY, 2023, 14Dai, ZhijieZhu, RonghuaSheng, ZhifengQin, GuijunLuo, XianghangQin, QunSong, ChunliLi, LipingJin, PingYang, GuopingCheng, YanxiangPeng, DanhongZou, ChongWang, LijuanShentu, JianzhongZhang, QinZhang, ZheYan, XiangFang, PingfeiYan, QiangyongYang, LingfengFan, XiaoLiu, WeiWu, BoCui, RongrongWu, XiyuXie, YutingShu, ChangShen, KaiWei, WenhuaLu, WeiChen, HongZhou, Zhiguang
- [8] A phase Ia dose-escalation trial of Ametumumab (a fully human monoclonal antibody against epidermal growth factor receptor) in patients with advanced solid malignanciesTHERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15Li, DaPan, HongWang, WeiXue, YananFang, YongLou, HaizhouPan, QinJin, WeiZheng, YuHan, WeidongZhu, KongliZhao, XianfengXu, RongHan, JinPan, Hongming
- [9] Safety, pharmacokinetic and pharmacodynamic results of a phase 1 single and double dose-escalation study of LymphoStat-B (human monoclonal antibody to BLyS) in SLE patients.ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S377 - S377Furie, RStohl, WGinzler, EBecker, MMishra, NChatham, WMerrill, JTWeinstein, AMcCune, WJZhong, JFreimuth, W
- [10] Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation studyLANCET INFECTIOUS DISEASES, 2018, 18 (04): : 410 - 418Beigel, John H.Voell, JocelynKumar, ParagRaviprakash, KanakatteWu, HuaJiao, Jin-AnSullivan, EddieLuke, ThomasDavey, Richard T., Jr.